Health and Healthcare

Biogen : BIIB

All Biogen Articles

607 Articles

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 10, 2016 at 8:40 AM EST

Major Biotech Short Interest Continues to Be Mixed

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most…

Lee Jackson | Feb 1, 2016 at 9:50 AM EST

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the…

Lee Jackson | Jan 28, 2016 at 10:10 AM EST

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha…

Chris Lange | Jan 28, 2016 at 8:35 AM EST

Short Sellers Increase Bets in Major Biotechs

Short interest increased in most of these selected biotech stocks for the most recent settlement date.

Chris Lange | Jan 27, 2016 at 8:35 AM EST

How Biogen Won at Earnings in Q4

Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.

Chris Lange | Jan 26, 2016 at 1:50 PM EST

What to Expect From Biogen Earnings

Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.

Lee Jackson | Jan 14, 2016 at 8:35 AM EST

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry…

Chris Lange | Jan 13, 2016 at 8:35 AM EST

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…

Jon C. Ogg | Jan 6, 2016 at 8:40 AM EST

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels,…

Chris Lange | Dec 28, 2015 at 8:40 AM EST

Short Interest Remains Mixed in Major Biotechs

The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in…

Paul Ausick | Dec 10, 2015 at 1:10 PM EST

Apple, Google, Tesla Are World’s Most Innovative Companies

Over the past 10 years the single, most innovative company in the world has been Apple, according to the Boston…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Nov 25, 2015 at 9:06 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the short interest data on the top biotech companies.

1 … 20 21 22 23 24 … 41

Biogen : BIIB

All Biogen Articles

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Short Sellers Increase Bets in Major Biotechs

How Biogen Won at Earnings in Q4

What to Expect From Biogen Earnings

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

Short Interest Remains Mixed for Major Biotechs

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Short Interest Remains Mixed in Major Biotechs

Apple, Google, Tesla Are World’s Most Innovative Companies

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Biogen : BIIB

All Biogen Articles

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Short Sellers Increase Bets in Major Biotechs

How Biogen Won at Earnings in Q4

What to Expect From Biogen Earnings

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

Short Interest Remains Mixed for Major Biotechs

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Short Interest Remains Mixed in Major Biotechs

Apple, Google, Tesla Are World’s Most Innovative Companies

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line